vusolimogene oderparepvec
AXP000010.2 · Oncolytic virus
- Platform
- HSV-1 (RH018A strain)
- Originator
- Replimune
- Sponsor
- Replimune
Names
| Name | Type | Source |
|---|---|---|
| vusolimogene oderparepvec | preferred name, INN | curator, ncit |
| Tudriqev | brand | fda |
| RP1 ambiguous | code | ncit |
| vusolimogene oderparepvec-wtpg | synonym | fda |
Virus
- Role
- Oncolytic
- Family
- Orthoherpesviridae
- Virus
- herpes simplex virus 1 (NCBI Taxonomy 10298)
- Strain
- RH018A
- Replication
- conditionally replicating
- Modifications
- RL1 (ICP34.5) and US12 (ICP47) deleted
- Transgenes
- CSF2, GALV-GP R-
- Route
- intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C158074
- Wikidata
- Q141304044
- FDA UNII
- 45KLN7N6UV
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| FDA | US | 2026-08-06 | conditional | Tudriqev | Advanced melanoma, with nivolumab (accelerated approval) | source |
Clinical trials (8)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07862530 | Neoadjuvant RP2 + Nivolumab in Patients With Melanoma | Not yet recruiting | Phase 2 | 2026-12-31 | 2028-02-27 | 34 | MelanomaCutaneous Melanoma Resectable, Melanoma |
| NCT06898970 | Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma | Recruiting | Phase 2 | 2026-01-09 | 2029-10-31 | 18 | Angiosarcoma; Angiosarcoma, Adult |
| NCT06264180 | VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] | Recruiting | Phase 3 | 2024-07-11 | 2030-09-30 | 400 | Advanced Melanoma |
| NCT06067061 | "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer | Terminated | Phase 1/2 | 2024-04-05 | 2025-05-07 | 2 | Triple Negative Breast Neoplasms |
| NCT06216938 | RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis | Recruiting | Early phase 1 | 2024-03-07 | 2028-03-31 | 25 | Melanoma |
| NCT04050436 | Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer | Active not recruiting | Phase 2 | 2019-10-08 | 2025-09 | 231 | Advanced Cutaneous Squamous Cell Carcinoma; Cutaneous Squamous Cell Carcinoma; Metastatic Cutaneous Squamous Cell Carcinoma |
| NCT03767348 | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) | Active not recruiting | Phase 2 | 2017-09-20 | 2028-06 | 340 | Cutaneous Melanoma; Microsatellite Instability-High (MSI-H); Non-Small Cell Lung Cancer (NSCLC); Non-melanoma Skin Cancer (NMSC) |
| NCT06590480 | An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma | No longer available | Advanced Melanoma |
Unconfirmed matches (1)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT05858229 | Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1. | Active not recruiting | Phase 1/2 | 2023-06-16 | 2025-12 | 12 | RP1; Squamous Cell Carcinoma | intervention named: RP1 |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40627813 | RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE). | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | cited by trial NCT03767348 |
| PMID 31399043 | Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1. | Journal for immunotherapy of cancer | 2019 | cited by trial NCT03767348 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41775431 | Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling. | Journal for immunotherapy of cancer | 2026 | name in title: vusolimogene oderparepvec |
| PMID 42346244 | The Evolving Role of Intralesional Therapy in In-Transit Melanoma. | Current oncology (Toronto, Ont.) | 2026 | name in abstract: vusolimogene oderparepvec |
| PMID 42582160 | Biodistribution, shedding, and transmissibility of vusolimogene oderparepvec (RP1). | Frontiers in oncology | 2026 | name in title: vusolimogene oderparepvec |
| PMID 42832393 | Vusolimogene oderparepvec (Tudriqev) - an oncolytic viral therapy for melanoma. | The Medical letter on drugs and therapeutics | 2026 | name in title: vusolimogene oderparepvec |
| PMID 42925389 | Vusolimogene Oderparepvec: First Approval. | Drugs | 2026 | name in title: vusolimogene oderparepvec |
| PMID 42988789 | Vusolimogene oderparepvec-wtpg (Tudriqev): a new engineered viral immunotherapy for intratumoral use. | Immunopharmacology and immunotoxicology | 2026 | name in title: vusolimogene oderparepvec-wtpg |
| PMID 40733704 | Advances in Oncolytic Viral Therapy in Melanoma: A Comprehensive Review. | Vaccines | 2025 | name in abstract: vusolimogene oderparepvec |
| PMID 41148835 | The Evolution, Current Landscape, and Future Prospects of Oncolytic Virotherapy in Melanoma: Talimogene Laherparepvec and Beyond. | Cells | 2025 | name in abstract: vusolimogene oderparepvec |
Notes
FDA accelerated approval 6 Aug 2026 as Tudriqev (vusolimogene oderparepvec-wtpg), with nivolumab, in advanced melanoma. Second transgene is a gibbon ape leukaemia virus envelope glycoprotein (GALV-GP R-), which is viral, so not in targets. Transgenes moved from targets to virus.tsv (spec 0.2).
How to cite
vusolimogene oderparepvec (AXP000010.2). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000010.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.